Investment Analysts’ Weekly Ratings Changes for Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals (NASDAQ: MDGL) has recently received a number of price target changes and ratings updates:

  • 5/18/2019 – Madrigal Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
  • 5/15/2019 – Madrigal Pharmaceuticals had its price target lowered by analysts at Citigroup Inc from $200.00 to $186.00. They now have a “buy” rating on the stock.
  • 5/9/2019 – Madrigal Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
  • 5/9/2019 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They wrote, “We attribute the beat to strong performance across and U.S. Generics (-12.3% Y/Y), stronger gross margins, and lower SG&A expense.””
  • 5/1/2019 – Madrigal Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
  • 4/18/2019 – Madrigal Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/17/2019 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 4/15/2019 – Madrigal Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.

Shares of NASDAQ:MDGL traded down $1.15 during mid-day trading on Wednesday, hitting $94.10. The stock had a trading volume of 3,428 shares, compared to its average volume of 141,881. The company has a market cap of $1.47 billion, a PE ratio of -42.39 and a beta of 1.07. Madrigal Pharmaceuticals Inc has a 12-month low of $91.56 and a 12-month high of $325.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.98) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.00) by $0.02. During the same quarter in the previous year, the company posted ($0.45) earnings per share. As a group, sell-side analysts predict that Madrigal Pharmaceuticals Inc will post -4.25 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Pearl River Capital LLC acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at about $29,000. First Mercantile Trust Co. grew its stake in shares of Madrigal Pharmaceuticals by 52.2% during the 4th quarter. First Mercantile Trust Co. now owns 624 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 214 shares during the period. Advisor Group Inc. grew its stake in shares of Madrigal Pharmaceuticals by 19.3% during the 1st quarter. Advisor Group Inc. now owns 656 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 106 shares during the period. Quantamental Technologies LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter valued at $90,000. Finally, Great West Life Assurance Co. Can grew its stake in shares of Madrigal Pharmaceuticals by 59.1% during the 4th quarter. Great West Life Assurance Co. Can now owns 985 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 366 shares during the period. 60.89% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Further Reading: What are Institutional Investors?

Receive News & Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.